Evinova will operate as a separate
health-tech business within AstraZeneca
Evinova’s globally-scaled digital health
solutions are evidence-led, science-based and human
experience-driven to serve clinical trial sponsors, clinical
research organisations (CROs), clinical trial site care teams and
patients
First strategic collaborations with
globally-leading CROs Parexel and Fortrea enable Evinova’s digital
health solutions to be offered to their wide customer base
AstraZeneca today launches Evinova, set to be a leading provider
of digital health solutions to better meet the needs of healthcare
professionals, regulators and patients. With long-term backing from
AstraZeneca and strategic collaborations with Parexel and Fortrea,
Evinova offers globally-scaled digital products and services to the
life sciences and healthcare sector.
Evinova will prioritise bringing to market established and
scaled digital technology solutions already being used globally by
AstraZeneca to optimise clinical trial design and delivery. This
will reduce the time and cost of developing new medicines, bring
care closer to home for patients and reduce the burden on health
systems. Evinova will also pursue opportunities in digital remote
patient monitoring and digital therapeutics with a pipeline of
digital innovations in these areas.
Drawing on AstraZeneca’s deep experience of developing novel
therapeutics and with insights from thousands of patients and
clinical researchers, Evinova will provide established technology
solutions to pharma, biotech and CROs to support clinical research
globally. The technologies have already been used in the successful
delivery of multiple AstraZeneca-sponsored clinical trials in over
40 countries.
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “The
future of medicine development can be accelerated with digital
solutions. We believe Evinova’s combination of scientific expertise
and track record in developing AI-enabled digital technologies at
scale, provides a real opportunity to fundamentally improve patient
care, drive healthcare transformation and reduce carbon
emissions.”
Cristina Duran, President of Evinova, said: “We are excited to
bring the portfolio of globally-scaled digital solutions developed
to serve AstraZeneca’s drug development pipeline to the wider life
sciences community. We believe this will help propel the sector
forward in digital health, as we know healthcare professionals and
regulators need digital solutions that work across pharma and
support patients broadly. Coming from within the sector and with
proven experience, Evinova will be uniquely placed to deliver
science-based, evidence-led and human experience-driven solutions
with the aim of improving patient experience and outcomes.”
Globally-leading CROs Parexel and Fortrea have entered into
agreements to offer Evinova digital health solutions to their wide
customer base. To accelerate industry adoption and sustain and
expand the global reach of its digital products, Evinova is
collaborating with Accenture and Amazon Web Services.
Evinova will combine clinical and regulatory experience gained
at AstraZeneca with its deep expertise in digital technology
spanning strategy and development, digital product development,
data science and AI, user experience design and behavioural
science. In addition to digital solutions, Evinova will offer
custom scientific solutions, including remote patient monitoring
and novel endpoint solutions, as well as trial design and
consulting services.
Notes
Evinova products and solutions
Evinova has co-created with patients the Evinova drug
development suite, a suite of digital solutions that aims to bring
benefits to all participants – patients, healthcare professionals
and researchers. The suite includes:
Evinova unified trial solution: A global GxP-validated solution
for patients, clinical trial site staff and clinical trial sponsor
staff to improve delivery of clinical trials. It enables the
delivery of traditional, hybrid and decentralised clinical trials
while enhancing the patient experience. The unified trial solution
supports direct collection of primary and secondary endpoint data
including novel digitally-enabled endpoints and connected medical
devices and sensors at both the trial site and patient’s home. It
also supports services for virtual visits including
direct-to-patient delivery of medicines, telehealth, remote patient
monitoring and human biological sample tracking. Patient
interaction is available through an easy-to-use, engaging patient
app available in more than 40 countries and 80 languages. Site
interaction is available through a single-sign-on portal.
Evinova study design and planning: Uses AI and machine learning
algorithms to aide clinical development and operations teams to
design the optimal study considering critical design variables.
Teams can design their study, get automatic costings and assess
operational feasibility based on actual data from that indication
at a country and site level. They can view historic data and
forecast future trends. The module also contains models to estimate
the study’s carbon footprint and impact on patient experience.
Teams can accelerate decision-making through collaboration and
scenario comparison capabilities.
Evinova portfolio management: Supports clinical programme and
trial management, reporting and governance through transparent
real-time insights and predictive analytics. It provides a complete
picture of the portfolio across all phases and allows for tracking
of clinical programmes and trials at global, regional, country and
site level. It uses predictive algorithms to provide future key
milestones, enabling study leaders to understand deviations from
plans and supporting appropriate intervention.
Digital health
The application of digital health technologies is seen as a
solution to reduce healthcare costs, while also helping to improve
patient experience and outcomes. Starting from around 6% of GDP in
2006-10, the combined public health and long-term care expenditure
for OECD countries is projected to reach at least 9.5% in 2060. In
BRIICS countries, spending ratios will also increase significantly,
reaching around 10% of GDP by 2060 unless cost-containment policies
are implemented.1 Based on 2018 healthcare spend information,
McKinsey estimates that digital health interventions alone have the
potential to save the US healthcare system nearly $500bn if fully
adopted.2
Digital health is a large (+$900bn by 2032) and growing (13.6%
CAGR 2022-2032) market. The market for R&D digital health and
care delivery with remote patient monitoring, together make up
approximately 60% of the total digital health market3. The
remaining 40% consists of screening and diagnostics, wellness and
disease prevention, supply of therapies and digital pharmacies.
Digital health technology and clinical research
A significant part of the cost and time of the drug development
process is in the clinical trials, rather than designing molecules.
However, they are vital to the drug development and approval
process and critical in enabling access to innovative medicines.
Studies estimate that it now costs up to $2bn to bring a new drug
to market4 and according to one study the average length of time
from the start of clinical testing to approval is 7.1 years.5
Across the industry, almost 80% of clinical trials fail to meet
recruiting timelines6 and only 3-5% of eligible cancer patients
join a clinical trial.7 Many groups, including marginalised racial
and ethnic groups, women, and other populations are
underrepresented in clinical trials.8
A recent AstraZeneca article published in Nature Medicine, lead
author Cristina Duran, demonstrated that the implementation of
digital health technology in clinical trials can improve the
patient experience with accelerated timelines and reduced
costs.9
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development, and commercialisation
of prescription medicines in Oncology, Rare Diseases, and
BioPharmaceuticals, including Cardiovascular, Renal &
Metabolism, and Respiratory & Immunology. Based in Cambridge,
UK, AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. Please visit
astrazeneca.com and follow the Company on Social Media @AstraZeneca.
Evinova
Evinova is a health-tech business, accelerating the delivery of
better health outcomes by propelling the life sciences sector
forward in digital health, from the inside. Through our application
of science-based expertise, evidence-led rigour, and human
experience-driven insight, our digital solutions are deliberately
designed so that everyone can reach better health outcomes
together. Evinova is a health-tech business within the AstraZeneca
Group.
Contacts
For details on how to contact the Investor Relations Team,
please click here. For Media contacts, click here.
References
- OECD. What future for health spending? Available at:
https://www.oecd.org/economy/health-spending.pdf. Accessed November
2023.
- McKinsey & Company. Healthtech in the fast lane: What is
fueling investor excitement? Available at:
https://www.mckinsey.com/industries/life-sciences/our-insights/healthtech-in-the-fast-lane-what-is-fueling-investor-excitement.
Accessed November 2023.
- Precedence Research. Digital Health Market (By Component:
Software, Hardware, and Services; By Technology: Telehealthcare
[Telehealth and Telecare], mHealth [Apps and Wearables], Digital
Health Systems [E-prescribing Systems and Electronic Health
Records], and Health Analytics) - Global Market Size, Trends
Analysis, Segment Forecasts, Regional Outlook 2023 – 2032.
Available at:
https://www.precedenceresearch.com/digital-health-market. Accessed
November 2023.
- Deloitte. Deloitte pharma study: Drop-off in returns on R&D
investments. Available at:
https://www2.deloitte.com/ch/en/pages/press-releases/articles/deloitte-pharma-study-drop-off-in-returns-on-r-and-d-investments-sharp-decline-in-peak-sales-per-asset.html.
Accessed November 2023.
- Deloitte. Deloitte pharma study: Drop-off in returns on R&D
investments. Available at:
https://www2.deloitte.com/ch/en/pages/press-releases/articles/deloitte-pharma-study-drop-off-in-returns-on-r-and-d-investments-sharp-decline-in-peak-sales-per-asset.html.
Accessed November 2023.
- Clinical Trials Arena. Clinical trial delays: America’s patient
recruitment dilemma. Available at:
https://www.clinicaltrialsarena.com/features/featureclinical-trial-patient-recruitment/.
Accessed November 2023.
- Baquet, C.R., Commiskey, P., Daniel Mullins, C., Mishra, S.I.,
Recruitment and participation in clinical trials:
socio-demographic, rural/urban, and health care access predictors.
Cancer Detect Prev. 2006;30(1):24-33. Available at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276312/. Accessed
November 2023.
- Schwartz, A.L, Aslan, M., Morris, A.M., Halpern, S.D., Why
diverse clinical trial participation matters. N Engl J Med 2023;
388:1252-1254. Available at:
https://www.nejm.org/doi/full/10.1056/NEJMp2215609#article_references.
Accessed November 2023.
- Durán, C.O., Bonam, M., Bj�rk, E. et al. Implementation of
digital health technology in clinical trials: the 6R framework. Nat
Med (2023). Available at:
https://doi.org/10.1038/s41591-023-02489-z. Accessed November
2023.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231120504578/en/
Brendan McEvoy 1-302-885-2677
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024